<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>DUPIXENT (dupilumab) injection, for subcutaneous use</title>
</head>
<body>
    <div id="content">
        <h1>DUPIXENT (dupilumab) injection, for subcutaneous use</h1>
        
        <div class="section">
            <h2>INDICATIONS AND USAGE</h2>
            <div class="content">
                <p>DUPIXENT is indicated for:</p>
                <p><strong>Atopic Dermatitis</strong></p>
                <ul>
                    <li>Treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.</li>
                    <li>DUPIXENT can be used with or without topical corticosteroids.</li>
                </ul>
                <p><strong>Asthma</strong></p>
                <ul>
                    <li>Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.</li>
                    <li>Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.</li>
                </ul>
                <p><strong>Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)</strong></p>
                <ul>
                    <li>Add-on maintenance treatment in adult patients with inadequately controlled CRSwNP.</li>
                </ul>
                <p><strong>Eosinophilic Esophagitis (EoE)</strong></p>
                <ul>
                    <li>Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE).</li>
                </ul>
                <p><strong>Prurigo Nodularis</strong></p>
                <ul>
                    <li>Treatment of adult patients with prurigo nodularis.</li>
                </ul>
            </div>
        </div>
        
        <div class="section">
            <h2>DOSAGE AND ADMINISTRATION</h2>
            <div class="content">
                <p>Some dosage information would go here...</p>
            </div>
        </div>
        
        <div class="section">
            <h2>CONTRAINDICATIONS</h2>
            <div class="content">
                <p>DUPIXENT is contraindicated in patients who have known hypersensitivity to dupilumab or any excipients of DUPIXENT.</p>
            </div>
        </div>
    </div>
</body>
</html>